Peptuno
GH-Axis Peptides
Featured

Product details

CJC-1295 without DAC (also known as Modified GRF 1-29 or ModGRF 1-29) is a 29-amino-acid GHRH analog with four amino-acid substitutions (Ala2→D-Ala, Asn8→Gln, Gly15→Ala, Met27→Leu) that confer protection against DPP-4 cleavage and serum protease degradation. The molecule signals through the GHRH receptor to produce pulsatile GH release that closely resembles physiological secretion patterns, distinct from the more sustained drug-affinity-complex (DAC) version, which has substantially longer plasma half-life via covalent albumin binding.

Peptuno supplies CJC-1295 no-DAC as the acetate salt, lyophilized, ≥99.0% HPLC. The no-DAC form is most commonly paired with a GHSR-pathway agonist (Ipamorelin, GHRP-2, or GHRP-6) in GH-axis research workflows, the dual-pathway combination produces additive GH-release signals beyond either component alone, and the canonical CJC-1295 + Ipamorelin blend is one of the most-requested SKUs in the catalog (sold as the dedicated cjc-1295-ipamorelin combination vial). Research labs typically prefer the 5 mg or 10 mg fills for in vivo dose-titration work.

FAQ

What's the difference between CJC-1295 with DAC and without DAC?
Both are based on the same Modified GRF 1-29 core sequence, but the DAC (Drug Affinity Complex) version has a maleimido-propionyl-Lys30 modification that allows covalent binding to serum albumin, dramatically extending plasma half-life from minutes (no-DAC) to roughly a week (DAC). The clinical/research consequence is fundamentally different pharmacokinetic profiles: the no-DAC form produces pulsatile GH release that mimics physiological secretion patterns, while the DAC form produces a sustained elevation that suppresses the natural pulse architecture. Most physiological-research workflows use the no-DAC form because it preserves natural pulse architecture; the DAC form is more common in sustained-elevation research contexts.
Why is CJC-1295 almost always combined with Ipamorelin in practice?
CJC-1295 signals through the GHRH receptor; Ipamorelin signals through the GHSR (ghrelin receptor). These are two parallel input pathways that both drive somatotroph GH release, and they synergize rather than compete, combining a GHRH-pathway agonist with a GHSR-pathway agonist produces GH-release magnitudes larger than either component alone at comparable individual doses. The standard ratio for the combined product is 1:1 by mass (most commonly 2+2 mg or 5+5 mg per vial). Peptuno supplies pre-blended co-lyophilized vials under the cjc-1295-ipamorelin SKU, which is preferred over the buyer mixing the two in solution because the analytical packet certifies the actual ratio in the released vial.
How is CJC-1295 typically reconstituted and stored after opening?
Lyophilized CJC-1295 reconstitutes cleanly in bacteriostatic water for injection at typical research and compounding concentrations. The reconstituted solution is reasonably stable when held at -20 °C as single-use aliquots, but degradation accelerates with freeze-thaw cycling, the operational guidance for the GH-axis class is to aliquot immediately into the smallest workable single-use volumes and limit thaw cycles to three or fewer. The lyophilized vial itself follows the standard 24-month re-test window at -20 °C; the COA carries a documented re-test date for buyers planning recurring orders.

Certificate of Analysis (COA)

The per-lot COA for this product will appear here.

Related products